Please login to the form below
Global Blood Therapeutics
This page shows the latest Global Blood Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Pfizer completes acquisition of Global Blood Therapeutics for $5.4bn
Pfizer has announced the completion of its acquisition of Global Blood Therapeutics (GBT), a biopharma focusing on drug discovery and development of treatments for rare blood disorders including sickle cell disease ... SCD is a lifelong, incurable
Latest news
-
Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
The acquisition will help accelerate research into sickle cell disease. Pfizer and Global Blood Therapeutics (GBT) have announced that Pfizer will acquire GBT. ... GBT focuses on drug discovery and development for rare blood disorders and Pfizer has an
-
MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Global Blood Therapeutics (GBT) a British marketing authorisation for Oxbryta – also known as voxelotor – for both adult and paediatric patients 12 ... the destruction of red
-
Global Blood Therapeutics’ treatment for patients with sickle cell disease approved in Europe
Global Blood Therapeutics (GBT) has announced the European Commission’s (EC) decision to grant a marketing authorisation for Oxbryta (voxelotor) for the treatment of haemolytic anaemia caused by sickle cell disease ... has been shown to break the
-
Bluebird bio’s sickle cell gene therapy shows early-study benefit
When patients have copies of the functional gene, their red blood cells can produce anti-sickling haemoglobin which decreases the amount of the faulty sickled haemoglobin. ... This includes Global Blood Therapeutics’ Oxbryta (voxelotor), which
-
FDA backs GBT’s sickle cell drug Oxbryta
Global Blood Therapeutics has secured US approval for Oxbryta, the second new treatment for sickle cell disease (SCD) to get a nod from the FDA this year. ... painful vaso-occlusive crises (VOCs) that result when the misshapen red cells block blood
More from news
Approximately 4 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Medscape Medical Affairs
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
